Angiotensin converting enzyme (ACE) inhibition and mechanisms of skeletal muscle weakness in chronic obstructive pulmonary disease (COPD)

Not Applicable

Completed

• Conditions: Chronic obstructive pulmonary disease (COPD); Respiratory; Other chronic obstructive pulmonary disease

• Registration Number: ISRCTN05581879
• Lead Sponsor: Imperial College London (UK)

Brief Summary

2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/24556825

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-10-31
• Study Completion: 2012-05-01
• Last Update Posted: 3 March 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Adult patients (greater than 18 years, either sex) with COPD diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. Only patients with quadriceps weakness will be enrolled into this randomised controlled trial (RCT).

Exclusion Criteria

1. Clinically unstable patients (within one month of exacerbation)
2. Those with a permanent pacemaker (which is a contraindication to magnetic stimulation), or significant co-morbidity
3. Patients with an accepted indication for ACE inhibition (left ventricular dysfunction, diabetes) or a contraindication such as renovascular disease
4. Creatinine clearance (estimated) less than 50 ml/min
5. Hypotension
6. Use of anticoagulants (contraindication to biopsy) or angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II (ATII) receptor antagonists
7. Allergy to ACE-I
8. Pregnancy
9. Patients who have participated in a pulmonary rehabilitation programme within the past three months

Study & Design

• Study Type: Interventional
• Study Design: Not specified